Individuals who are usually at risk of developing Alzheimer’s can take part in pre-screening visits at every mobile site stop. Global Alzheimer’s Platform Foundation (GAP) has introduced a new mobile health site to lower barriers to the participation of underrepresented communities in Alzheimer’s clinical trials. Around 1% of the African Americans and Hispanics with Alzheimer’s take part […]
GAP-Net Site Brigham and Women’s Hospital Center for Alzheimer Research & Treatment (CART), was featured in their local news station about the importance of volunteer participation in clinical research. A local hospital is now part of a global effort to test a drug that may delay the devastating impact of Alzheimer’s disease. The progressive neurological […]
GAP President John Dwyer was quoted in the Wall Street Journal speaking about how the Centers for Medicare and Medicaid Services coverage decision limits Alzheimer’s patients. The commercial failure of Biogen Inc.’s drug Aduhelm is putting new focus on the state of research into the causes of Alzheimer’s disease. More than six million people in the U.S. are […]
GAP-Net Site, Neurological Associates of Albany, was featured in the news about a new trial they are participating in. Over the last five years, Jim Manuel says he slowly started to lose bits and pieces of his life. Pieces so small, it was easy for his wife and kids to think he was imagining it. […]
GAP-Net Site El Faro Health and Therapeutics’ Dr. James Falcon was interviewed about the new research center. Starr County, a rural area along the Texas-Mexico border, has one of the highest rates of Alzheimer’s disease in the country. It’s not clear why. But physicians at a new research and treatment center in the area hope to […]
GAP President John Dwyer was quoted in AlzForum about the Centers for Medicare and Medicaid Services (CMS) National Coverage Decision (NCD) to only cover the drug Aduhlem for those in enrolled in a qualifying clinical trial. The verdict is in—but what now? The Centers for Medicare and Medicaid Services will only cover aducanumab in the context of […]
GAP President John Dwyer spoke about the Bio-Hermes study and why enrolling minority populations are a priority. Metro Orlando clinical trial hopes to speed up Alzheimer’s diagnoses for minorities Black people are twice as likely as white people to develop Alzheimer’s disease — Latinx people, 1.5 times as likely. But barriers including access to health […]
GAP-Net sites Baylor College of Medicine Alzheimer’s Disease and Memory Disorders Center and the Lou Ruvo Center for Brain Health at the Cleveland Clinic in Las Vegas are collaborating on a film project to bring awareness of the prevalence of Alzheimer’s disease in the Latino community. Assistant director Aaron Thomas slams the clapperboard Saturday to […]
GAP-Net site El Faro Health & Therapeutics was featured in the Houston Chronicle. The disease took Noemi Fleming’s elderly mother slowly, the first hints in repeated anecdotes or phrases. Then misplaced keys and bills. Then, Fleming caught her mother walking outside in the middle of the night, looking for the newspaper. “Mama, it’s 1 o’clock […]
GAP President John Dwyer was quoted in Pink Sheet in regard to the Centers for Medicare and Medicaid Services’ proposed National Coverage Decision. The Centers for Medicare and Medicaid Services’ proposed eligibility criteria for the research sites capable of conducting clinical trials for monoclonal antibody drugs for Alzheimer’s disease could be met in just 28 […]
GAP President John Dwyer, on behalf of the organization, joined other Alzheimer’s advocates in Washington D.C. for the ‘Rally for Access’ on March 15, 2022. The ‘Rally for Access’ gathered these organizations to remind the public what is at stake if the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) is accepted. […]
A new seven-figure ad campaign takes aim – again – at Medicare’s pending coverage decision on Alzheimer’s disease anti-amyloid drugs. UsAgainstAlzheimer’s launched the $1 million-plus national effort Sunday, including a TV ad that ran across the the day’s morning talk news shows. The group is the latest to push back on the Centers for Medicare […]
GAP-Net Site Charter Research’s Jeff Pohlig, CEO, wrote an Op-Ed about how volunteering can improve your health and your community. Unfortunately, over 90% of research studies are delayed because of slow recruitment. These delays may be affecting the treatment of your neighbor, loved one, co-worker or friend. Floridians facing Alzheimer’s need clinical trial volunteers to […]
GAP President John Dwyer was featured in Pink Sheet talking about the cost of Aduhelm affecting the Centers for Medicare and Medicaid Services NCD. US Medicare coverage policy is supposed to be fenced off from considerations about the cost of a prescription drug (or other item or service). But the notion that the cost of […]
Being Patient answers some common questions regarding the Centers for Medicare and Medicaid Services (CMS) proposal, and GAP President John Dwyer mentions how this could affect future Alzheimer’s trials and treatments. The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects […]
GAP President John Dwyer was quoted in NJ.com about the future of Alzheimer’s treatments if the CMS National Coverage Decision (NCD) proposal is approved. Every day in this country, an estimated 1,000 people progress from moderate Alzheimer’s dementia to the final and most severe stage of the disease. That’s a grim statistic in its own […]
GAP President John Dwyer was quoted in Politico talking about the difficulty of having a diverse population pool in Alzheimer’s clinical trial, and how unlike that is to achieve if the CMS proposal is approved. Drugmakers and patient advocacy groups are waging a campaign to cast Medicare officials as villains after the program limited coverage […]
Watch GAP President John Dwyer and GAP’s Senior Advisor, Dr. Lynne Hughes, talk about our Ixico partnership and our Bio-Hermes study.
New GAP-Net site El Faro Health and Therapeutics has opened in Rio Grande City, TX. The below article was translated from Spanish to English. The original, Spanish version is linked at the bottom. A new clinical research center to study Alzheimer’s and its impact among Hispanics, the group with the highest prevalence of this disease […]
Alzheimer’s World Directs Eyes on the Rio Grande Valley as Acclaimed Family Physician Opens New Facility in Rio Grande City with Highest Alzheimer’s Rate in the Country The Global Alzheimer’s Platform Foundation® (GAP) and Dr. Antonio Falcon celebrated the opening of El Faro Health & Therapeutics in Rio Grande City, TX on Saturday, marking a […]
GAP-Net Site, El Faro Health and Therapeutics, was opened in Starr County, Texas led by Drs. Antonio and James Falcon. El Faro Health & Therapeutics will be the first private clinical research site in Starr County, TX. This groundbreaking initiative will bring critical Alzheimer’s-related research and care to a community that has been historically underrepresented […]
GAP is proud to support the grand opening of #GAPNet El Faro Health and Therapeutics, the first private research site in Starr County, Texas. Starr County is a 97% Hispanic Community with the highest prevalence of Alzheimer’s disease in America. Legendary Starr County physician and Baylor College of Medicine Trustee, Dr. Antonio ‘Tony’ Falcon is […]
GAP President John Dwyer commends President Joe Biden on his commitment to fight Alzheimer’s, as well as calls on Congress to pass ARPA-H. Normally, presidential proclamations aren’t news. However, as the United States sinks deeper into a worsening Alzheimer’s public health crisis, President Joe Biden is making his priorities on the disease abundantly clear. Prior […]
Microsoft and Gates Ventures founder, Bill Gates, mentions GAP’s Bio-Hermes study to the World Dementia Council. We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems and the seventh leading cause of death worldwide. Its […]